Skip to main content
profile image
Selected Works of Walter J. Urba, MD, PhD
Article
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Blood (2001)
  • John E. Janik, National Institutes of Health
  • Langdon L. Miller, Pfizer
  • Edward L. Korn, National Institutes of Health
  • Diane Stevens, Science Applications International Corporation
  • Brendan D. Curti, National Institutes of Health
  • John W. Smith, University of Michigan
  • Mario Sznol, Vion Pharmaceuticals, Inc.
  • Kevin C. Conlon, Memorial Sloan Kettering Cancer Center
  • William Sharfman, National Institutes of Health
  • Walter J. Urba, Providence Portland Medical Center
  • Barry L. Gause, National Institutes of Health
  • Dan L. Longo, National Institutes of Health
Link
Disciplines
Publication Date
April 1, 2001
DOI
10.1182/blood.V97.7.1942
Citation Information
John E. Janik, Langdon L. Miller, Edward L. Korn, Diane Stevens, et al.. "A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma." Blood Vol. 97 Iss. 7 (2001) p. 1942 - 1946
Available at: http://works.bepress.com/walter-urba/228/